Status:
SUSPENDED
Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis
Lead Sponsor:
Biocells Medical
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
The goal of this clinical trial is to learn if intravenous infusion of allogeneic mesenchymal stem cell (MSC)-derived exosomes can slow disability progression and improve neurological function in adul...
Eligibility Criteria
Inclusion
- Age 18-65 years.
- Diagnosis of progressive multiple sclerosis (primary or secondary) confirmed
- EDSS score 3.0-6.5.
Exclusion
- Relapse or corticosteroid treatment within 3 months before screening.
- Other significant neurological or autoimmune disorders.
- Active infection, malignancy, or uncontrolled systemic disease.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07146087
Start Date
July 1 2020
End Date
December 31 2027
Last Update
August 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biocells Medical
Warsaw, Poland